{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Cancer+%28Mcrc%29&page=2", "query": { "condition": "Metastatic Colorectal Cancer (Mcrc)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Cancer+%28Mcrc%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T22:48:20.052Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04660812", "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "m-FOLFOX-6 regimen", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2021-05-10", "completion_date": "2025-09-05", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660812" }, { "nct_id": "NCT04575922", "title": "Nivolumab+Ipilimumab+RT in MSS mCRC", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-10-05", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2022-09-08", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575922" }, { "nct_id": "NCT00931840", "title": "A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "EZN-2208, Cetuximab and Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enzon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2009-06", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2011-09-20", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 35, "location_summary": "Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931840" }, { "nct_id": "NCT03549338", "title": "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Cancer Metastatic", "Carcinoma" ], "interventions": [ { "name": "Sym004", "type": "DRUG" }, { "name": "Futuximab", "type": "DRUG" }, { "name": "Modotuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-11-29", "completion_date": "2019-03-09", "has_results": true, "last_update_posted_date": "2020-09-28", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03549338" }, { "nct_id": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma (RRMM)", "Metastatic Colorectal Cancer (mCRC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Higher-Risk Myelodysplastic Syndrome (HR-MDS)", "Acute Myeloid Leukemia (AML)", "Newly Diagnosed Intermediate/High-Risk MDS" ], "interventions": [ { "name": "KPT-8602", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2016-01", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 26, "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649790" }, { "nct_id": "NCT00642746", "title": "Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2008-03", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-09-26", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642746" }, { "nct_id": "NCT07011576", "title": "A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer", "Colorectal Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "fruquintinib", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-09-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 14, "location_summary": "Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Maple Grove", "state": "Minnesota" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011576" }, { "nct_id": "NCT03442569", "title": "PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 56, "start_date": "2018-03-09", "completion_date": "2024-12-02", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 5, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442569" }, { "nct_id": "NCT05061017", "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Metastatic Colorectal Carcinoma", "Refractory Melanoma" ], "interventions": [ { "name": "Pixatimod", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cyclophosphamide (low dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-12-09", "completion_date": "2024-03-18", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061017" }, { "nct_id": "NCT07446322", "title": "FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ras-mutated Metastatic Colorectal Cancer", "mCRC", "MSS Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Pelareorep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-04-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-25T22:48:20.052Z", "location_count": 3, "location_summary": "Homewood, Alabama • Florham Park, New Jersey • Canton, Ohio", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Florham Park", "state": "New Jersey" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07446322" } ] }